Veliparib (ABT-888)

目录号:S1004 别名: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Phase 3。

规格 价格 库存 购买数量  
In DMSO RMB 1277.12 现货
RMB 973.01 现货
RMB 3010.72 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献70篇:

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Phase 3。
特性 ABT-888增强常见癌症疗法的效果,比如放射疗法和烷基化剂。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外研究

ABT-888有效抑制PARP,作用于PARP-1和PARP-2时Ki值分别为5.2和2.9 nM。ABT-888降低肺癌H460细胞中克隆基因的存活率,且抑制DNA修复。[1]ABT-888抑制C41细胞,EC50为2 nM。[2] ABT-888和放射物联用减少肿瘤血管的形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NXGy[HBQU2mwYYPlJGF{e2G7 NGrIWnE{OCCvaX6= NV3KTJdwUW6qaXLpeIlwdiCxZjDQRXJROSC5aYToJGVEPTBib3[gNE4xODJizszN M1zu[VE6QDh6N{[w
Jurkat NELyO5pMcW6jc3WgRZN{[Xl? NHjGRYE6PiCq M{\lSWROW09? MXLJcohq[mm2aX;uJI9nKFCDUmCxJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSC5aYToJGVEPTBib3[gN{DPxE1? NHKyR3kzOzh3MEG5PS=>
Capan1 NXrTU4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\CZYw4OiCq MoS4SG1UVw>? NID1Z|RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJTS0F{IHflcoUhdXW2YYTl[EBpfW2jbjDDZZBidjFiY3XscJMhf2m2aDDJR|UxKG:oIEO5Mlch|ryP NWHyZW9vOjR|OUizPFM>
DT40 NH34UJNEgXSxdH;4bYMhSXO|YYm= NGDpcW04OiCq MmjmSG1UVw>? NFztfnVEgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ MY[yOFkzOjV6Nx?=
ML-1 NHK1cIpCeG:ydH;0bYMhSXO|YYm= Ml76Nk42KM7:TR?= NHKzUIIzPCCq MWTEUXNQ NHHrempUgW6ncnfpd5Rq[2GubImg[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXNiaX6gUWwuOSClZXzsdy=> MW[yOFg6PTF|NR?=
HCT-116 MoTaT4lv[XOnIFHzd4F6 MUmwMlUh|ryP MXuyOEBp NWfLSFFqWEGUUDDhZ5Rqfmm2eTDk[YNz\WG|ZYO= MXyyN|A2PDJzMx?=
UM-SCC1 NEfvdIZEgXSxdH;4bYMhSXO|YYm= NFn1WZcyOCEQvF2= NIG4T|EzPCCq MUnS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NU[2VpM1OjF7MUK2NlA>
FaDu NUniTmRvS3m2b4TvfIlkKEG|c3H5 MYSxNEDPxE1? MmHSNlQhcA>? MXzS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NYC3bJhXOjF7MUK2NlA>
PC-3 NE\pOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLnNVAh|ryP MYrJcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6qaXLpeIlwdiCrbjDjc4xwdnliZn;ycYF1cW:wwrC= MoTWNlE2PzF7MUK=
EoL-1-cell NH3zclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnjTWM2OD1zLkC3PVgh|ryP M2mxOHNCVkeHUh?=
NCI-SNU-5 NWXTc5pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13TPGlEPTB;Mz6xNlg1OSEQvF2= MXPTRW5ITVJ?
BV-173 MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwNEW0NFkh|ryP M2LOXXNCVkeHUh?=
HCC1806 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC1TWM2OD13Lke1NVc{KM7:TR?= Mo\IV2FPT0WU
COLO-680 M2T0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZwMkG0NFYh|ryP MoDCV2FPT0WU
HCC2218 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTdwN{m3NFQh|ryP M3fDUnNCVkeHUh?=
SK-MEL-24 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTdwOEG5NlQh|ryP M{D4cHNCVkeHUh?=
NCI-H720 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3iTWM2OD16LkSzOlA{KM7:TR?= MkHFV2FPT0WU
KASUMI-1 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRThwOEmyOlYh|ryP NGHGWolUSU6JRWK=
HAL-01 M4G3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\CTWM2OD17Lki4OlIh|ryP MWTTRW5ITVJ?
CAL-33 NGm0b41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDEPFJiUUN3ME2xNE41OzRizszN NH65PW9USU6JRWK=
SK-MEL-1 NFjWNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:3U4pKSzVyPUGyMlQ3PjNizszN NFTwVZRUSU6JRWK=
Ramos-2G6-4C10 M{XWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTibVB5UUN3ME2xNk41PzV{IN88US=> MoLRV2FPT0WU
KY821 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPqOFloUUN3ME2xNk41QDVizszN NUf2b3Y1W0GQR1XS
HEC-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF{LkmxPVYh|ryP NIK3WnJUSU6JRWK=
SK-NEP-1 NGHpPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXZYRDUUN3ME2xN{4yPjZizszN NHjHNXhUSU6JRWK=
MN-60 NUPLeXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPETWM2OD1zMz61N|g6KM7:TR?= MYTTRW5ITVJ?
DU-145 MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPCd5BzUUN3ME2xN{46ODV|IN88US=> MknDV2FPT0WU
EW-3 NYjscJpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TLTmlEPTB;MUSuOVU3PSEQvF2= M{XNNnNCVkeHUh?=
OS-RC-2 M2TMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF3Lkm1PFkh|ryP Ml76V2FPT0WU
RPMI-8226 MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fRV2lEPTB;MU[uNlA1OiEQvF2= NF[4dHFUSU6JRWK=
ChaGo-K-1 NULhXVRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XneGlEPTB;MU[uOVMzPSEQvF2= M3XvXHNCVkeHUh?=
DEL MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW0dIlEUUN3ME2xOk43PzF5IN88US=> MVzTRW5ITVJ?
GP5d NF3hNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvMbGNJUUN3ME2xO{4xPTNizszN MnTFV2FPT0WU
COLO-668 MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTZTWM2OD1zNz62Nlk1KM7:TR?= MlvPV2FPT0WU
H9 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF6LkK4N|Mh|ryP NXvzW3FKW0GQR1XS
NKM-1 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\rSGlEPTB;MUiuOVEyQSEQvF2= MXLTRW5ITVJ?
KYSE-150 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\jUo1KSzVyPUG4Mlk6QDZizszN NECzWXNUSU6JRWK=
Daoy MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF7LkW2OFkh|ryP NUjDbIEzW0GQR1XS
ECC10 NV3WNYRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJyLke0OVUh|ryP MlfRV2FPT0WU
A388 NXW1eXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWniSJNSUUN3ME2yNU46ODlzIN88US=> MXvTRW5ITVJ?
MHH-NB-11 M1fz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPFb4RKSzVyPUKzMlE{PjNizszN M1rWTXNCVkeHUh?=
HCC1937 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTmcXdrUUN3ME2yOE44PDZizszN M{KzVHNCVkeHUh?=
TGBC11TKB Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\BTWM2OD1{NT62PFY{KM7:TR?= NV63[YNmW0GQR1XS
CTV-1 MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljmTWM2OD1{NT64PVY6KM7:TR?= NGDjclVUSU6JRWK=
NCI-H2029 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7JTWM2OD1{Nj60NlM5KM7:TR?= MYHTRW5ITVJ?
HLE NG\TU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPXfodKSzVyPUK3MlA2PCEQvF2= NWHN[YRUW0GQR1XS
NCI-H1693 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHOc5ZVUUN3ME2yO{4zQDl6IN88US=> M3\C[3NCVkeHUh?=
HCC70 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnEZ|dXUUN3ME2yO{44OjR4IN88US=> MYjTRW5ITVJ?
BEN MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJ5Lkm1OlYh|ryP NV7JSJJvW0GQR1XS
LB771 NF;6W|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrNPJNQUUN3ME2yPE45Ozd|IN88US=> M3LXSXNCVkeHUh?=
697 M{jtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnpOlBKSzVyPUK5MlAzOzVizszN NIjHdWtUSU6JRWK=
LU-139 M3fuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ7LkO3OFgh|ryP MlL1V2FPT0WU
EW-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfhO2FUUUN3ME2yPU4{QDF2IN88US=> MnjkV2FPT0WU
MOLT-13 NIjJOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLmTWM2OD1{OT6zPFE1KM7:TR?= M17tNXNCVkeHUh?=
L-363 NF:5N5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonXTWM2OD1{OT60O|k5KM7:TR?= NG[yNWZUSU6JRWK=
EM-2 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\yNmlEPTB;MkmuOFkxOSEQvF2= NXnQfZVCW0GQR1XS
RS4-11 NXG5WHF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTNyLkSyOFEh|ryP NInVOG5USU6JRWK=
A2780 NWK0fGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLyTWM2OD1|MD63OFU4KM7:TR?= MnTLV2FPT0WU
KU812 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrsTWM2OD1|Mj6zOlQzKM7:TR?= NF3IbGNUSU6JRWK=
COLO-684 NH7wO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTN|LkO1PVkh|ryP NGPEVItUSU6JRWK=
MFE-280 NHr0S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LzN2lEPTB;M{OuN|g5QSEQvF2= MnHnV2FPT0WU
KG-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\vPFZKSzVyPUOzMlYxODFizszN MW\TRW5ITVJ?
JVM-3 NF72cHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrlTFBIUUN3ME2zOU42QDZ6IN88US=> MljGV2FPT0WU
MV-4-11 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN3Lki0PVkh|ryP M1izcHNCVkeHUh?=
LAMA-84 NHj5WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3oW3NKSzVyPUO2Mlc{PDVizszN M1H3cXNCVkeHUh?=
MOLT-16 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\sU2pNUUN3ME2zOk46PTJizszN MlPlV2FPT0WU
H4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fvTWlEPTB;M{euOVY4KM7:TR?= NYrkZZh7W0GQR1XS
T47D NUm3VVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n5RmlEPTB;M{euO|AyQCEQvF2= Ml[yV2FPT0WU
CAL-54 NG\0Z|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TsXWlEPTB;M{euPVY3KM7:TR?= M4jTZXNCVkeHUh?=
SW982 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\4eWlEPTB;M{iuNFk6QCEQvF2= MV\TRW5ITVJ?
IGROV-1 M{LCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7zTWM2OD1|OT6zN|A1KM7:TR?= NF:4R|ZUSU6JRWK=
NB14 NUHCU|FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGwTINKSzVyPUSwMlcxOzFizszN MUjTRW5ITVJ?
HCC1187 M3L6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHKNFNKSzVyPUSxMlI4PzFizszN NYXIeZljW0GQR1XS
SBC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILo[oFKSzVyPUSxMlMxPjNizszN NHPEdGRUSU6JRWK=
KARPAS-45 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;Ud4xKSzVyPUSxMlQ5OThizszN MWfTRW5ITVJ?
MOLT-4 NFXoW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG5TWM2OD12Mj6yOVM5KM7:TR?= MoKwV2FPT0WU
JVM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfUWoI{UUN3ME20Nk46OjB5IN88US=> NX7KW4t4W0GQR1XS
A4-Fuk NEHJd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\4dm14UUN3ME20N{42PjlzIN88US=> NH:wc3pUSU6JRWK=
MDA-MB-361 MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLHTWM2OD12Mz64OFE1KM7:TR?= MW\TRW5ITVJ?
BALL-1 NE\pfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfmOVc3UUN3ME20N{46PTN{IN88US=> M3;pZXNCVkeHUh?=
T98G NWfTUplOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XQNmlEPTB;NESuPFUyPyEQvF2= M{Tmc3NCVkeHUh?=
Mo-T MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOzOZNKSzVyPUS1MlY{QDlizszN NULvOHRtW0GQR1XS
MHH-PREB-1 NXzSS|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojuTWM2OD12NT63OVg2KM7:TR?= MVrTRW5ITVJ?
ALL-PO NXfXdWdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjHfVJKSzVyPUS3MlM4QTFizszN M3jmVHNCVkeHUh?=
NCI-H510A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILDZYlKSzVyPUS3MlkxOzRizszN NGrvOXNUSU6JRWK=
ML-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDRdphKSzVyPUS5Mlc5PTZizszN NXvyW2h2W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
体内研究 ABT-888推迟NCI-H460 移植瘤模型的肿瘤生长。ABT-888在B16F10 和9L 移植瘤模型中抑制PARP,从而增强temozolomide的抗癌活性。[1]ABT-888和其他细胞毒素药剂联用作用于MX-1移植瘤模型时显示出强抗癌效力。[2]在A375和 Colo829移植瘤模型中按肿瘤大小,每千克分别加3和12.5 mg ABT-888,可以看到肿瘤内95%以上PAR被抑制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

体外PARP实验:

在含有50 mM Tris (pH 为8.0), 1 mM DTT,和 4 mM MgCl2的缓冲溶液中进行酶活性测定。PARP反应包含1.5 μM [3H]-NAD+ (1.6 μCi/mmol), 200 nM 生物素组蛋白 H1, 200 nM slDNA,及1 nM PARP-1或4 nM PARP-2酶。在加有100 μL 反应液的 96孔板上进行SPA检测。在50 μL含有PARP和DNA的2×酶液混合物中加入50 μL 2×NAD+基底混合物,反应开始。加入150 μL 1.5 mM 苯甲酰胺反应停止。170uL反应终止液转移到链霉亲和素包被的闪熔镀层上,温育1小时,用微型板块闪烁计数器计数。
细胞实验:[2]
+ 展开
  • Cell lines: C41细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 0.5小时
  • Method: 在96孔板上用ABT-888处理C41细胞0.5小时。用1 mM H2O2破坏DNA10分钟,PARP被激活。用冰冻的PBS冲洗细胞,然后用预冷的甲醇/丙酮(按7:3比例混合)在−20oC下固定10 分钟。风干后,用PBS再溶解,然后用溶有5%脱脂奶粉的PBS- Tween封闭液(0.05%)在室温下阻断0.5小时。细胞和PAR抗体按1:50比例在封闭液中室温下温育1小时,然后用PBS-Tween-20冲洗5分钟,然后加入荧光素-5(6)-异硫氰酸酯 (FITC)-联用的二抗和1μg/mL DAPI封闭液中室温下温育1小时。PBS-Tween-20冲洗5分钟后,用荧光微型版计数器分析数据。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带NCI-H460, H460, B16F10和9L移植瘤的C57BL/6鼠
  • Formulation: 在含0.9% NaCl溶液中配制,调节pH 为4.0
  • Dosages: 25或3.125 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 244.29
化学式

C13H16N4O

CAS号 912444-00-9
储存条件 powder
in solvent
别名 NSC 737664

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Ovarian Cancer AbbVie July 2015 Phase 1
NCT02289690 Completed Small Cell Lung Cancer AbbVie October 13 2014 Phase 1|Phase 2
NCT02210663 Completed Advanced Solid Tumors AbbVie July 2014 Phase 1
NCT02158507 Active not recruiting Metastatic Triple Negative Breast Cancer University of Alabama at Birmingham|Scariot Foundation|GlaxoSmithKline|AbbVie July 2014 Not Applicable

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Veliparib (ABT-888) | Veliparib (ABT-888)供应商 | 采购Veliparib (ABT-888) | Veliparib (ABT-888)价格 | Veliparib (ABT-888)生产 | 订购Veliparib (ABT-888) | Veliparib (ABT-888)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID